Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Acorda Therapeutics, Inc." (ACOR) Report Updated: Oct 24, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Acorda Therapeutics, Inc." (ACOR)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up downgrade
service keys

"Acorda Therapeutics, Inc."© quotemedia

Company Profile

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinsonís disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.